BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

507 related articles for article (PubMed ID: 26241169)

  • 1. Personalized approaches to active immunotherapy in cancer.
    Ophir E; Bobisse S; Coukos G; Harari A; Kandalaft LE
    Biochim Biophys Acta; 2016 Jan; 1865(1):72-82. PubMed ID: 26241169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Xenogeneic therapeutic cancer vaccines as breakers of immune tolerance for clinical application: to use or not to use?
    Strioga MM; Darinskas A; Pasukoniene V; Mlynska A; Ostapenko V; Schijns V
    Vaccine; 2014 Jul; 32(32):4015-24. PubMed ID: 24837511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent Development and Clinical Application of Cancer Vaccine: Targeting Neoantigens.
    Pan RY; Chung WH; Chu MT; Chen SJ; Chen HC; Zheng L; Hung SI
    J Immunol Res; 2018; 2018():4325874. PubMed ID: 30662919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The present status and future prospects of peptide-based cancer vaccines.
    Hirayama M; Nishimura Y
    Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in Therapeutic Cancer Vaccines.
    Wong KK; Li WA; Mooney DJ; Dranoff G
    Adv Immunol; 2016; 130():191-249. PubMed ID: 26923002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engineered Nanoparticles for Cancer Vaccination and Immunotherapy.
    Aikins ME; Xu C; Moon JJ
    Acc Chem Res; 2020 Oct; 53(10):2094-2105. PubMed ID: 33017150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cellular therapy approaches harnessing the power of the immune system for personalized cancer treatment.
    Bastien JP; Minguy A; Dave V; Roy DC
    Semin Immunol; 2019 Apr; 42():101306. PubMed ID: 31604534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo induction of dendritic cell-mediated cytotoxicity against allogeneic pancreatic carcinoma cells.
    Stift A; Friedl J; Dubsky P; Bachleitner-Hofmann T; Benkoe T; Brostjan C; Jakesz R; Gnant M
    Int J Oncol; 2003 Mar; 22(3):651-6. PubMed ID: 12579320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
    Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B
    J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current state and perspectives of dendritic cell vaccination in cancer immunotherapy.
    Farkas A; Conrad C; Tonel G; Borbenyi Z; Kemeny L; Dobozy A; Nestle FO
    Skin Pharmacol Physiol; 2006; 19(3):124-31. PubMed ID: 16612139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Precision cancer immunotherapy: optimizing dendritic cell-based strategies to induce tumor antigen-specific T-cell responses against individual patient tumors.
    Osada T; Nagaoka K; Takahara M; Yang XY; Liu CX; Guo H; Roy Choudhury K; Hobeika A; Hartman Z; Morse MA; Lyerly HK
    J Immunother; 2015 May; 38(4):155-64. PubMed ID: 25839441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
    Seledtsov VI; Goncharov AG; Seledtsova GV
    Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer vaccines.
    Butterfield LH
    BMJ; 2015 Apr; 350():h988. PubMed ID: 25904595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A polyvalent cellular vaccine induces T-cell responses against specific self-antigens overexpressed in chronic lymphocytic B-cell leukemia.
    Kronenberger K; Nössner E; Frankenberger B; Wahl U; Dreyling M; Hallek M; Mocikat R
    J Immunother; 2008 Oct; 31(8):723-30. PubMed ID: 18779747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Personalized vaccines for cancer immunotherapy.
    Sahin U; Türeci Ö
    Science; 2018 Mar; 359(6382):1355-1360. PubMed ID: 29567706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Personalized cancer vaccines.
    Jain KK
    Expert Opin Biol Ther; 2010 Dec; 10(12):1637-47. PubMed ID: 20979567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Next generation approaches for tumor vaccination.
    Patel A; Kaufman HL; Disis ML
    Chin Clin Oncol; 2017 Apr; 6(2):19. PubMed ID: 28482672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor cell lysates as immunogenic sources for cancer vaccine design.
    González FE; Gleisner A; Falcón-Beas F; Osorio F; López MN; Salazar-Onfray F
    Hum Vaccin Immunother; 2014; 10(11):3261-9. PubMed ID: 25625929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modified Vaccinia virus Ankara-based vaccines in the era of personalized immunotherapy of cancer.
    Bendjama K; Quemeneur E
    Hum Vaccin Immunother; 2017 Sep; 13(9):1997-2003. PubMed ID: 28846477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Colorectal cancer vaccines: Tumor-associated antigens
    Wagner S; Mullins CS; Linnebacher M
    World J Gastroenterol; 2018 Dec; 24(48):5418-5432. PubMed ID: 30622371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.